What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Subjects will receive two doses of 3.75 µg of CoVLP adjuvanted with AS03 adjuvant given 21 days apart into the deltoid region of the alternating arm (each arm will be injected once)”In the company’s words, NCT04636697 on ClinicalTrials.gov
- Tested for
- SARS-CoV-2 Infection
- Main trialPhase 2/3
- “This Phase 2/3 study is a multi-portion design to confirm that the chosen formulation and dosing regimen of CoVLP has an acceptable immunogenicity and safety profile. The Phase 3 portion is an event-driven, randomized, observer blinded, placebo-controlled design that will evaluate the efficacy and safety of the CoVLP formulation compared to placebo. Subjects will be followed for safety and immunogenicity for a period of 12 months after the last vaccination.”In the company’s words, NCT04636697 on ClinicalTrials.gov
- Other names
- Intramuscular vaccine
Other drugs for SARS-CoV-2 Infection
- MaravirocHealthBio, Inc. · Phase 2/3
- REGENECYTEStemCyte, Inc. · Phase 3
- VYD2311Invivyd, Inc. · Phase 3
- SecutrelvirShionogi · Phase 3
- IbuzatrelvirPfizer · Phase 3
- TozorakimabAstraZeneca · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2/3Active, not recruiting | 25 Aug 2021 | Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults | |
| Phase 3Withdrawn | 31 May 2022 | Phase 3 Study to Evaluate the Lot Consistency of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026